Rationale for current therapies in Parkinson's disease.

Rationale for current therapies in Parkinson's disease.

Item
http://www.wikidata.org/entity/Q35548168
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.Psychosis in Parkinson's disease.Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disordersRecent important trials of pharmacotherapy in Parkinson's disease.Parkinson's disease management strategies.Therapeutic applications of antibodies in non-infectious neurodegenerative diseasesThe Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo.Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.Sensitive and rapid determination of amantadine without derivatization in human plasma by LC–MS/MS for a bioequivalence study.
P2860

Rationale for current therapies in Parkinson's disease.

Item
http://www.wikidata.org/entity/Q35548168
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rationale for current therapies in Parkinson's disease.
@ast
Rationale for current therapies in Parkinson's disease.
@en
type
label
Rationale for current therapies in Parkinson's disease.
@ast
Rationale for current therapies in Parkinson's disease.
@en
prefLabel
Rationale for current therapies in Parkinson's disease.
@ast
Rationale for current therapies in Parkinson's disease.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Rationale for current therapies in Parkinson's disease.
@en
P2093
P2860
P304
P31
P356
10.1517/14656566.4.10.1747
P407
P433
P478
P50
P577
P698
P921